Rozlytrek (Entrectinib) – NSCLC | HongKong DengYue Medicine

  • Generic Name/Brand Name: ​Entrectinib / Rozlytrek ®
  • Indications: NSCLC
  • Dosage Form: ​Capsules
  • Specification: 100 mg , 200 mg × 30 capsules/box

Entrectinib Application Scope

ROZLYTREK® is indicated for the treatment of adult and pediatric patients (≥12 years old) with ROS1-positive, metastatic non-small cell lung cancer (NSCLC) who have not received prior ROS1-targeted therapy.NTRK gene fusion-positive solid tumors (locally advanced or metastatic) in patients who have no satisfactory alternative therapies, regardless of tumor type, including both adult and pediatric populations.

rozlytrek entrectinib
rozlytrek entrectinib

Entrectinib Characteristics

  • Ingredients: Entrectinib

  • Properties:​ Tyrosine kinase inhibitor (TKI); targeted therapy

  • Packaging Specification:​ 100 mg & 200 mg capsules × 30 capsules/box

  • Storage:​ Store at 20–25°C; protect from moisture and light

  • Expiry Date: As per package label

  • Executive Standard: ​FDA / EMA approval standard

  • Approval Number: FDA NDA 209063

  • Date of Revision: Latest EMA SmPC: March 2023

  • Manufacturer: Roche / Genentech

Guidelines for the Use of Rozlytrek

  • Dosage and Administration:

    • Recommended Dose: 600 mg orally once daily (continuous dosing)

    • Administration: Take orally, with or without food; swallow capsules whole

    • Missed Dose:​ If missed, take as soon as remembered; do not double dose

  • Adverse Reactions:

    • Common Adverse Reactions:

      • Fatigue

      • Constipation, diarrhea

      • Dizziness, cough

      • Edema

    • Serious Adverse Reactions:

      • Severe cardiac events (e.g., congestive heart failure, QT prolongation)

      • Hepatotoxicity

      • Neurological effects (cognitive disorders, seizures)

  • Contraindications: Hypersensitivity to excipients

  • Precautions:

    • Monitor liver function, ECG, and neurological status.

    • Dose adjustment for severe adverse events or hepatic impairment

    • Use contraception during and after treatment

Entrectinib Interactions

  • CYP3A inhibitors/inducers may alter entrectinib exposure

  • Avoid strong CYP3A modulators if possible

  • Monitor for additive toxicity with other TKIs

 

Note:

  • If there is a new packaging for the drug, the new packaging shall prevail. The above information is sourced from DengYue Medicine.
  •  This content is for reference only. Prescription drugs must be used under a doctor’s guidance and purchased from authorized sources.
Contact Us
Contact Form Demo